534 related articles for article (PubMed ID: 25381128)
1. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
Paiva B; Chandia M; Puig N; Vidriales MB; Perez JJ; Lopez-Corral L; Ocio EM; Garcia-Sanz R; Gutierrez NC; Jimenez-Ubieto A; Lahuerta JJ; Mateos MV; San Miguel JF
Haematologica; 2015 Feb; 100(2):e53-5. PubMed ID: 25381128
[No Abstract] [Full Text] [Related]
2. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Rawstron AC; Child JA; de Tute RM; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Feyler S; Ross FM; Cook G; Jackson GH; Morgan GJ; Owen RG
J Clin Oncol; 2013 Jul; 31(20):2540-7. PubMed ID: 23733781
[TBL] [Abstract][Full Text] [Related]
3. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.
Landgren O; Owen RG
Cytometry B Clin Cytom; 2016 Jan; 90(1):14-20. PubMed ID: 26147584
[TBL] [Abstract][Full Text] [Related]
4. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Paiva B; Vidriales MB; Sempere A; Tarín F; Colado E; Benavente C; Cedena MT; Sánchez J; Caballero-Velazquez T; Cordón L; Garces JJ; Simoes C; Martínez-Cuadrón D; Bernal T; Botella C; Grille S; Serrano J; Rodríguez-Medina C; Algarra L; Alonso-Domínguez JM; Amigo ML; Barrios M; García-Boyero R; Colorado M; Pérez-Oteyza J; Pérez-Encinas M; Costilla-Barriga L; Sayas MJ; Pérez O; González-Díaz M; Pérez-Simón JA; Martínez-López J; Sossa C; Orfao A; San Miguel JF; Sanz MÁ; Montesinos P;
Leukemia; 2021 Aug; 35(8):2358-2370. PubMed ID: 33526859
[TBL] [Abstract][Full Text] [Related]
5. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
Venner CP; Connors JM; Sutherland HJ; Shepherd JD; Hamata L; Mourad YA; Barnett MJ; Broady R; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Nitta J; Power MM; Toze CL; Smith CA; Song KW
Leuk Lymphoma; 2011 Jan; 52(1):34-41. PubMed ID: 21133716
[TBL] [Abstract][Full Text] [Related]
6. BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.
Requirand G; Robert N; Boireau S; Vincent L; Seckinger A; Bouhya S; Ceballos P; Cartron G; Hose D; Klein B; Moreaux J
Cytometry B Clin Cytom; 2019 May; 96(3):209-214. PubMed ID: 30417559
[TBL] [Abstract][Full Text] [Related]
7. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
Leleu X; Fouquet G; Hebraud B; Roussel M; Caillot D; Chrétien ML; Arnulf B; Szalat R; Garderet L; Benajiba L; Pegourie B; Regny C; Royer B; Caulier A; Stoppa AM; Garciaz S; Touzeau C; Chaleteix C; Fermand JP; Loiseau HA; Facon T; Attal M; Moreau P;
Leukemia; 2013 Nov; 27(11):2242-4. PubMed ID: 23558525
[No Abstract] [Full Text] [Related]
8. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.
Eckert C; Hagedorn N; Sramkova L; Mann G; Panzer-Grümayer R; Peters C; Bourquin JP; Klingebiel T; Borkhardt A; Cario G; Alten J; Escherich G; Astrahantseff K; Seeger K; Henze G; von Stackelberg A
Leukemia; 2015 Aug; 29(8):1648-55. PubMed ID: 25748682
[TBL] [Abstract][Full Text] [Related]
9. Assessment of minimal residual disease in myeloma and the need for a consensus approach.
Rawstron AC; Paiva B; Stetler-Stevenson M
Cytometry B Clin Cytom; 2016 Jan; 90(1):21-5. PubMed ID: 26202864
[TBL] [Abstract][Full Text] [Related]
10. Assessment of response to therapy in multiple myeloma by multiparameter flow cytometry. Usefulness of an eight-color single tube with monoclonal antibodies in dried formulation.
Carulli G; Tarasco A; Sammuri P; Ottaviano V; Domenichini C; Ciancia EM; Petrini M
Clin Ter; 2019; 170(5):e352-e356. PubMed ID: 31612192
[TBL] [Abstract][Full Text] [Related]
11. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.
de Tute RM; Rawstron AC; Gregory WM; Child JA; Davies FE; Bell SE; Cook G; Szubert AJ; Drayson MT; Jackson GH; Morgan GJ; Owen RG
Haematologica; 2016 Feb; 101(2):e69-71. PubMed ID: 26471484
[No Abstract] [Full Text] [Related]
14. Multiple myeloma, immunotherapy and minimal residual disease.
Kusenda J; Kovarikova A
Neoplasma; 2016; 63(5):651-8. PubMed ID: 27468868
[TBL] [Abstract][Full Text] [Related]
15. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
16. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
Martinez-Lopez J; Fernández-Redondo E; García-Sánz R; Montalbán MA; Martínez-Sánchez P; Pavia B; Mateos MV; Rosiñol L; Martín M; Ayala R; Martínez R; Blanchard MJ; Alegre A; Besalduch J; Bargay J; Hernandez MT; Sarasquete ME; Sanchez-Godoy P; Fernández M; Blade J; San Miguel JF; Lahuerta JJ;
Br J Haematol; 2013 Dec; 163(5):581-9. PubMed ID: 24117042
[TBL] [Abstract][Full Text] [Related]
17. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.
Paiva B; Gutiérrez NC; Rosiñol L; Vídriales MB; Montalbán MÁ; Martínez-López J; Mateos MV; Cibeira MT; Cordón L; Oriol A; Terol MJ; Echeveste MA; de Paz R; de Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Sureda A; Gorosquieta A; Alegre A; Martin A; Hernández MT; Lahuerta JJ; Bladé J; San Miguel JF;
Blood; 2012 Jan; 119(3):687-91. PubMed ID: 22128143
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.
Jimenez-Zepeda VH; Duggan P; Neri P; Chaudhry A; Murray K; Culham M; Luider J; Fourie T; Rashid-Kolvear F; Bahlis NJ
Leuk Lymphoma; 2016; 57(4):973-6. PubMed ID: 26450458
[No Abstract] [Full Text] [Related]
19. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma.
Paiva B; Azpilikueta A; Puig N; Ocio EM; Sharma R; Oyajobi BO; Labiano S; San-Segundo L; Rodriguez A; Aires-Mejia I; Rodriguez I; Escalante F; de Coca AG; Barez A; San Miguel JF; Melero I
Leukemia; 2015 Oct; 29(10):2110-3. PubMed ID: 25778100
[No Abstract] [Full Text] [Related]
20. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Paiva B; Vidriales MB; Cerveró J; Mateo G; Pérez JJ; Montalbán MA; Sureda A; Montejano L; Gutiérrez NC; García de Coca A; de Las Heras N; Mateos MV; López-Berges MC; García-Boyero R; Galende J; Hernández J; Palomera L; Carrera D; Martínez R; de la Rubia J; Martín A; Bladé J; Lahuerta JJ; Orfao A; San Miguel JF;
Blood; 2008 Nov; 112(10):4017-23. PubMed ID: 18669875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
